FAM65A promotes the progression and growth of lung squamous cell carcinoma in vivo and vitro

被引:0
作者
Chen, Fangjun [1 ]
Ren, Peng [2 ]
Xu, Rui [3 ]
Zhang, Jin [4 ]
Liang, Chaoyang [4 ]
Qiang, Guangliang [2 ]
机构
[1] China Japan Friendship Hosp, Dept Thorac Surg, Beijing, Peoples R China
[2] Peking Univ Third Hosp, Dept Thorac Surg, 49 North Garden Rd, Beijing 100191, Peoples R China
[3] China Japan Friendship Hosp, Dept Nucl Med, Beijing, Peoples R China
[4] China Japan Friendship Hosp, Dept Thorac Surg, Beijing, Peoples R China
关键词
FAM65A; Lung squamous cell carcinoma; Proliferation; Invasion; Metastasis; CANCER; EXPRESSION; GTPASES;
D O I
10.1186/s12885-024-12701-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundsCurrently, family with sequence similarity 65 member A (FAM65A) is reported as a pivotal regulator in various cancers. However, the effect of FAM65A in lung squamous cell carcinoma (LSCC) is still unclear, the prime objective of this research is to explore the role of FAM65A in LSCC.MethodsGene expression data and correlated clinical information were downloaded from the public database and the expression of FAM65A was detected. The expression of FAM65A was also detected in our collected clinical samples and LSCC cell lines. Survival package of R language was used to determine the survival significance of FAM65A. Proteins expression level was determined via western blot assay. Cell function experiments and in vivo experiments were performed to explore the effect of FAM65A on LSCC cell biological behaviors.ResultsFAM65A expression was significantly increased in LSCC clinical samples and cell lines. High FAM65A expression predicted poor prognosis in LSCC patients. After silencing FAM65A, the ability of LSCC cell proliferation, invasion and migration was decreased, and LSCC cell cycle was blocked. Moreover, in vivo experiments revealed that silencing FAM65A could inhibit LSCC cell proliferation.ConclusionsHigh FAM65A expression could enhance proliferative, invasive and migratory abilities of LSCC. FAM65A might be a novel biomarker of LSCC.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
    Ascione, Claudia Maria
    Napolitano, Fabiana
    Esposito, Daniela
    Servetto, Alberto
    Belli, Stefania
    Santaniello, Antonio
    Scagliarini, Sarah
    Crocetto, Felice
    Bianco, Roberto
    Formisano, Luigi
    [J]. CANCER TREATMENT REVIEWS, 2023, 115
  • [2] Lung Cancer 2020 Epidemiology, Etiology, and Prevention
    Bade, Brett C.
    Dela Cruz, Charles S.
    [J]. CLINICS IN CHEST MEDICINE, 2020, 41 (01) : 1 - +
  • [3] Dissecting the role of protein phosphorylation: a chemical biology toolbox
    Bilbrough, Tim
    Piemontese, Emanuele
    Seitz, Oliver
    [J]. CHEMICAL SOCIETY REVIEWS, 2022, 51 (13) : 5691 - 5730
  • [4] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Laversanne, Mathieu
    Sung, Hyuna
    Ferlay, Jacques
    Siegel, Rebecca L.
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) : 229 - 263
  • [5] Genomic basis for RNA alterations in cancer
    Calabrese, Claudia
    Davidson, Natalie R.
    Demircioglu, Deniz
    Fonseca, Nuno A.
    He, Yao
    Kahles, Andre
    Kjong-Van Lehmann
    Liu, Fenglin
    Shiraishi, Yuichi
    Soulette, Cameron M.
    Urban, Lara
    Greger, Liliana
    Li, Siliang
    Liu, Dongbing
    Perry, Marc D.
    Xiang, Qian
    Zhang, Fan
    Zhang, Junjun
    Bailey, Peter
    Erkek, Serap
    Hoadley, Katherine A.
    Hou, Yong
    Huska, Matthew R.
    Kilpinen, Helena
    Korbel, Jan O.
    Marin, Maximillian G.
    Markowski, Julia
    Nandi, Tannistha
    Pan-Hammarstrom, Qiang
    Pedamallu, Chandra Sekhar
    Siebert, Reiner
    Stark, Stefan G.
    Su, Hong
    Tan, Patrick
    Waszak, Sebastian M.
    Yung, Christina
    Zhu, Shida
    Awadalla, Philip
    Creighton, Chad J.
    Meyerson, Matthew
    Ouellette, B. F. Francis
    Wu, Kui
    Yang, Huanming
    Brazma, Alvis
    Brooks, Angela N.
    Goke, Jonathan
    Raetsch, Gunnar
    Schwarz, Roland F.
    Stegle, Oliver
    Zhang, Zemin
    [J]. NATURE, 2020, 578 (7793) : 129 - +
  • [6] Current cancer burden in China: epidemiology, etiology, and prevention
    Cao, Maomao
    Li, He
    Sun, Dianqin
    He, Siyi
    Yan, Xinxin
    Yang, Fan
    Zhang, Shaoli
    Xia, Changfa
    Lei, Lin
    Peng, Ji
    Chen, Wanqing
    [J]. CANCER BIOLOGY & MEDICINE, 2022, 19 (08) : 1121 - 1138
  • [7] CDC25B Mediates Rapamycin-induced Oncogenic Responses in Cancer Cells
    Chen, Run-qiang
    Yang, Qing-kai
    Lu, Bing-wen
    Yi, Wei
    Cantin, Greg
    Chen, Yan-ling
    Fearns, Colleen
    Yates, John R., III
    Lee, Jiing-Dwan
    [J]. CANCER RESEARCH, 2009, 69 (06) : 2663 - 2668
  • [8] PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
    Cimadamore, Alessia
    Massari, Francesco
    Santoni, Matteo
    Lopez-Beltran, Antonio
    Cheng, Liang
    Scarpelli, Marina
    Montironi, Rodolfo
    Moch, Holger
    [J]. CURRENT DRUG TARGETS, 2020, 21 (16) : 1664 - 1671
  • [9] Targeting Rho GTPase Signaling Networks in Cancer
    Clayton, Natasha S.
    Ridley, Anne J.
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [10] Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
    Dantoing, Edouard
    Piton, Nicolas
    Salaun, Mathieu
    Thiberville, Luc
    Guisier, Florian
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (12)